Floatz logo

m3814

Oncology

EMD Serono Research & Development Institute, Inc.Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Oncology cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
Romiplostim
Memorial Sloan Kettering Cancer Center
Phase 2BB
Trebananib
Takeda
Phase 2BB
Zoledronate
Institut Bergonié
Phase 3BB
Lapatinib
Deraya University
Phase 2B

View all 32 →

Same molecule, other indications

m3814 is also rated in:

Advanced Solid TumorsDormant
CCC
Indicative ·
52 / 100
View asset →
Unresectable Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Locally Advanced Unresectable Gallbladder CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →